FEATURED CONTRIBUTED CONTENT

Speak Out


Speak Out

Calling out Clinical Technology Think about your phone – maybe you are even reading this on it – and you’ll probably have an emotional reaction of some kind. It may or may not be a strong reaction, but odds are there is a certain and specific feeling your phone emotes in you. For something that […]

March 1, 2017 More Clinical »
Preparing for the Next Big Transformation


Preparing for the Next Big Transformation

TayganPoint Consulting Group conducted its inaugural survey this year in collaboration with Pharma Voice.  The intent of the survey was to explore the many issues Life Science Companies face as they transform and better understand how well they are prepared for driving transformation efforts.  The results are quite telling although not hugely surprising, given this […]

May 1, 2017 More Clinical »
Improved Patient Outcomes and Financial Performance


Improved Patient Outcomes and Financial Performance

Neither orphan drug manufacturers nor their patients with rare diseases are served well by the traditional multi-channel model of drug delivery and patient service. A new integrated model increases adherence and improves patient outcomes, which in turn leads to better financial performance for manufacturers.

May 18, 2017 More Clinical »
The Global Alzheimer’s Crisis: New Paradigms in Clinical Trials and Longitudinal Screening


The Global Alzheimer’s Crisis: New Paradigms in Clinical Trials and Longitudinal Screening

There is scientific knowledge. And there is public perception. And often, the two collide. Nowhere is this reality more explicit than with the current state of Alzheimer’s disease research. Without a definitive cause or diagnosis – and no cure in sight – many adults see no reason to assess their risk, or determine their cognitive […]

May 2, 2017 More Clinical »
Expediting Drug Approval


Expediting Drug Approval

For patients with serious and rare diseases, time is of the essence, and the traditional drug development process may take far too long. To speed innovative new drugs to market, the FDA has established four expedited programs that allow the development process to be compressed and evidence of the drug’s effectiveness gathered as efficiently as […]

April 3, 2017 More Clinical »
HBAdvantage: Leadership in Action – Spring 2017


HBAdvantage: Leadership in Action – Spring 2017

This year marks a special milestone for the Healthcare Businesswomen’s Association. Forty years ago, five courageous women  came together in New York with a shared passion to make the advertising and medical journal world of healthcare a place where women could not just survive but thrive. (Please turn to page 10 for more about the remarkable evolution/revolution of the HBA.) And since this […]

May 12, 2017 More Clinical »
Virtual Engagement – a Must-have Component of any Pharmaceutical Sales Strategy


Virtual Engagement – a Must-have Component of any Pharmaceutical Sales Strategy

In this episode, Michael Carlin talks about how Virtual Engagements are addressing the issue of limited physician access by pharmaceutical reps, including keys to success, measuring results, and the degree of success with these programs. There is also a related white paper entitled, “Driving Greater Access to Healthcare Professionals and Increasing Brand Performance.” It can be downloaded using the […]

May 22, 2017 More Clinical »
Rescue Studies:  Key Considerations for Getting Your Study Back on Track


Rescue Studies: Key Considerations for Getting Your Study Back on Track

In this episode, Dr. Steiger talks about rescue studies, specifically when to start thinking about bringing in a new vendor, what capabilities to look for in a vendor, three case studies and more. You can also download a related case study entitled “Implementing a Study Design Change Late in a Trial for Breast Cancer Indication” with the […]

May 10, 2017 More Clinical »
Driving Greater Access to Healthcare Professionals and Increasing Brand Performance


Driving Greater Access to Healthcare Professionals and Increasing Brand Performance

Virtual engagement strategies are evolving the way the pharmaceutical industry connects with key stakeholders. By using a blend of technology and experienced personnel to seamlessly connect brands to healthcare professionals, virtual engagement offers a solution to the trend of decreased in-person engagement opportunities via the traditional field representative model. This white paper examines how brands […]

May 22, 2017 More Clinical »
Implementing a Study Design Change Late in a Trial for Breast Cancer Indication


Implementing a Study Design Change Late in a Trial for Breast Cancer Indication

This eligibility study for a breast cancer indication began as a single-read model with six radiologists assigned. Based on the data submitted, the sponsor identified favorable results when the trial was well underway. Consequently, the sponsor sought a more robust approach, requiring a trial design change involving a double radiology read with adjudication. Now on […]

May 10, 2017 More Clinical »
FEEDBACK